Atlas Trials

Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab

Clinical trial NCT06104826 · UNKNOWN

Trial details

NCT number
NCT06104826
Sponsor
Newark Beth Israel Medical Center
Status
UNKNOWN
Study type
OBSERVATIONAL
Hemophilia A
Start date
2023-12-01
Primary completion
2024-12-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.